Highlights & Basics
- Rubella is typically a mild, self-limited, systemic infection caused by the rubella virus. Treatment of symptomatic rubella infection is largely supportive, as the illness is self-limited.
- The most important consequence of rubella infection is congenital rubella syndrome, which may result from infection during pregnancy. Specialty consultation is strongly recommended for pregnant women with exposure to rubella.
- Rubella immunization programs have eliminated endemic spread of the virus in the Americas; most cases are imported or associated with imported infections.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Images
Rubella rash
Koplik spots
Child with measles showing the characteristic red blotchy rash on his buttocks and back during the third day of the rash
The scarlet fever rash first appears as tiny red bumps on the chest and abdomen that may spread all over the body; looking like sunburn, it feels like a rough piece of sandpaper, and lasts about 2 to 5 days
Patient with a syphilitic roseola-like rash, similar to that of viral eczema, which developed on her buttocks and legs during the secondary stage of the disease
A conjunctival hemorrhage of the right eye of this patient with infectious mononucleosis
Tongue and palate of patient with infectious mononucleosis
Bullous erythema multiforme
Citations
Centers for Disease Control and Prevention. Rubella (German measles, three-day measles). Dec 2020 [internet publication].[Full Text]
Centers for Disease Control and Prevention. CDC Yellow Book 2024. Section 5: travel-associated infections and diseases - rubella. May 2023 [internet publication].[Full Text]
McLean HQ, Fiebelkorn AP, Temte JL, et al; Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2013 Jun 14;62(RR-04):1-34.[Abstract][Full Text]
Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2024. Nov 2023 [internet publication].[Full Text]
Centers for Disease Control and Prevention. Recommended adult immunization schedule for ages 19 years or older, United States, 2024. Nov 2023 [internet publication].[Full Text]
Centers for Disease Control and Prevention. Rubella/German measles: 2013 case definition. 2013 [internet publication].[Full Text]
1. Morse EE, Zinkham WH, Jackson DP. Thrombocytopenic purpura following rubella infection in children and adults. Arch Int Med. 1966 Apr;117(4):573-9.[Abstract]
2. World Health Organization. Rubella vaccines: WHO position paper - July 2020 - Note de synthèse: position de l'OMS concernant les vaccins antirubéoleux. 2020 [internet publication].[Full Text]
3. Ou AC, Zimmerman LA, Alexander JP Jr, et al. Progress toward rubella and congenital rubella syndrome elimination - worldwide, 2012-2022. MMWR Morb Mortal Wkly Rep. 2024 Feb 29;73(8):162-7.[Abstract][Full Text]
4. Centers for Disease Control and Prevention. Achievements in public health: elimination of rubella and congenital rubella syndrome - United States, 1969-2004. Morb Mortal Wkly Rep. 2005 Mar 25;54(11):279-82.[Abstract]
5. Centers for Disease Control and Prevention. Rubella (German measles, three-day measles). Dec 2020 [internet publication].[Full Text]
6. Papania MJ, Wallace GS, Rota PA, et al. Elimination of endemic measles, rubella, and congenital rubella syndrome from the Western hemisphere: the US experience. JAMA Pediatr. 2014 Feb;168(2):148-55.[Abstract][Full Text]
7. Lanzieri T, Haber P, Icenogle JP, et al. Rubella. In: Hamborsky J, Kroger A, Wolfe C, eds. CDC The Pink Book: Epidemiology and prevention of vaccine-preventable diseases. Aug 2021 [internet publication].[Full Text]
8. Pan American Health Organization; World Health Organization. Elimination of rubella and congenital rubella syndrome in the Americas. Fact Sheet 2015. Apr 2015 [internet publication].[Full Text]
9. O'Connor P, Jankovic D, Zimmerman L, et al. Progress toward rubella elimination - World Health Organization European Region, 2005-2019. MMWR Morb Mortal Wkly Rep. 2021 Jun 11;70(23):833-9.[Abstract][Full Text]
10. Centers for Disease Control and Prevention (CDC). Nationwide rubella epidemic--Japan, 2013. MMWR Morb Mortal Wkly Rep. 2013 Jun 14;62(23):457-62.[Abstract][Full Text]
11. Centers for Disease Control and Prevention. CDC Yellow Book 2024. Section 5: travel-associated infections and diseases - rubella. May 2023 [internet publication].[Full Text]
12. McLean HQ, Fiebelkorn AP, Temte JL, et al; Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2013 Jun 14;62(RR-04):1-34.[Abstract][Full Text]
13. World Health Organization. Rubella fact sheet. Oct 2019 [internet publication]. [Full Text]
14. Zimmerman LA, Knapp JK, Antoni S, et al. Progress Toward Rubella and Congenital Rubella Syndrome Control and Elimination - Worldwide, 2012-2020. MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):196-201.[Abstract][Full Text]
15. Lambert N, Strebel P, Orenstein W, et al. Rubella. Lancet. 2015 Jun 6;385(9984):2297-307.[Abstract]
16. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2024. Nov 2023 [internet publication].[Full Text]
17. Centers for Disease Control and Prevention. Recommended adult immunization schedule for ages 19 years or older, United States, 2024. Nov 2023 [internet publication].[Full Text]
18. Krow-Lucal E, Marin M, Shepersky L, et al. Measles, mumps, rubella vaccine (PRIORIX): recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Nov 18;71(46):1465-70.[Abstract][Full Text]
19. Maglione MA, Das L, Raaen L, et al. Safety of vaccines used for routine immunization of U.S. children: a systematic review. Pediatrics. 2014 Aug;134(2):325-37.[Abstract][Full Text]
20. Hviid A, Hansen JV, Frisch M, et al. Measles, mumps, rubella vaccination and autism: a nationwide cohort study. Ann Intern Med. 2019 Apr 16;170(8):513-20. [Abstract][Full Text]
21. Di Pietrantonj C, Rivetti A, Marchione P, et al. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev. 2021 Nov 22;11:CD004407.[Abstract]
22. Tingle AJ, Allen M, Petty RE, et al. Rubella-associated arthritis. I: comparative study of joint manifestations associated with natural rubella infection and RA 27/3 rubella immunisation. Ann Rheum Dis. 1986 Feb;45(2):110-4.[Abstract][Full Text]
23. Isaac BM, Zucker JR, Giancotti FR, et al. Rubella surveillance and diagnostic testing among a low-prevalence population, New York City, 2012-2013. Clin Vaccine Immunol. 2017 Sep;24(9):e00102-17.[Abstract][Full Text]
24. Gross PA, Portnoy B, Mathies AW Jr, et al. A rubella outbreak among adolescent boys. Am J Dis Child. 1970 Apr;119(4):326-31.[Abstract]
25. Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis. 2004 May 1;189 Suppl 1:S4-16.[Abstract][Full Text]
26. Ratnam S, Tipples G, Head C, et al. Performance of indirect immunoglobulin M (IgM) serology tests and IgM capture assays for laboratory diagnosis of measles. J Clin Microbiol. 2000 Jan;38(1):99-104.[Abstract][Full Text]
27. Jackson MA, Sommerauer JF. Human herpesviruses 6 and 7. Pediatr Infect Dis J. 2002 Jun;21(6):565-6.[Abstract]
28. American Academy of Pediatrics Committee on Infectious Diseases. Human herpesvirus 6 (including roseola) and 7. In: Kimberlin DW, Barnett ED, Lynfield R, et al, eds. 2021-2024 Report of the Committee on Infectious Diseases (32ND EDITION): red book. Elk Grove Village, IL: American Academy of Pediatrics; 2021.
29. Chiu SS, Cheung CY, Tse CY, et al. Early diagnosis of primary human herpesvirus 6 infection in childhood: serology, polymerase chain reaction, and virus load. J Infect Dis. 1998 Nov;178(5):1250-6.[Abstract][Full Text]
30. Tanz RR, Gerber MA, Kabat W, et al. Performance of a rapid antigen-detection test and throat culture in community pediatric offices: implications for management of pharyngitis. Pediatrics. 2009 Feb;123(2):437-44.[Abstract]
31. Doyle S, Kerr S, O'Keeffe G, et al. Detection of parvovirus B19 IgM by antibody capture enzyme immunoassay: receiver operating characteristic analysis. J Virol Methods. 2000 Nov;90(2):143-52.[Abstract]
32. Corcoran A, Doyle SJ. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. Med Microbiol. 2004 Jun;53(Pt 6):459-75.[Abstract][Full Text]
33. Vuorinen T, Vainionpaa R, Hyypia T. Five years' experience of reverse-transcriptase polymerase chain reaction in daily diagnosis of enterovirus and rhinovirus infections. Clin Infect Dis. 2003 Aug 1;37(3):452-5.[Abstract][Full Text]
34. Tilley PA, Walle R, Chow A, et al. Clinical utility of commercial enzyme immunoassays during the inaugural season of West Nile virus activity, Alberta, Canada. J Clin Microbiol. 2005 Sep;43(9):4691-5.[Abstract][Full Text]
35. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-associated infections & diseases - dengue. May 2023 [internet publication].[Full Text]
36. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-associated infections & diseases - chikungunya. May 2023 [internet publication].[Full Text]
37. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-associated infections & diseases - Zika. May 2023 [internet publication].[Full Text]
38. Centers for Disease Control and Prevention. Zika virus. Nov 2022 [internet publication].[Full Text]
39. Centers for Disease Control and Prevention. Zika virus: testing for Zika. Jun 2019 [internet publication].[Full Text]
40. Muller I, Brade V, Hagedorn HJ, et al. Is serological testing a reliable tool in laboratory diagnosis of syphilis? meta-analysis of eight external quality control surveys performed by the German Infection Serology Proficiency Testing Program. J Clin Microbiol. 2006 Apr;44(4):1335-41.[Abstract][Full Text]
41. Bruu AL, Hjetland R, Holter E, et al. Evaluation of 12 commercial tests for detection of Epstein-Barr virus-specific and heterophile antibodies. Clin Diagn Lab Immunol. 2000 May;7(3):451-6.[Abstract][Full Text]
42. Centers for Disease Control and Prevention. Rubella/German measles: 2013 case definition. 2013 [internet publication].[Full Text]
43. American Academy of Pediatrics, Kimberlin DW, Barnett ED, Lynfield R, et al. Red Book, 32nd Edition (2021). 2021-2024 Report of the Committee on Infectious Diseases, 32nd Edition. 2021. Elk Grove Village, IL: American Academy of Pediatrics; 2021.
44. Public Health England. Notifiable diseases and causative organisms: how to report. May 2023 [internet publication].[Full Text]
45. Young MK, Cripps AW, Nimmo GR, et al. Post-exposure passive immunisation for preventing rubella and congenital rubella syndrome. Cochrane Database Syst Rev. 2015 Sep 9;(9):CD010586.[Abstract][Full Text]
46. Sherman FE, Michaels RH, Kenny FM. Acute encephalopathy (encephalitis) complicating rubella: report of cases with virological studies, cortisol-production determinations, and observations at autopsy. JAMA. 1965 May 24;192:675-81.[Abstract]
47. Bechar M, Davidovich S, Goldhammer G, et al. Neurological complications following rubella infection. J Neurol. 1965 1982;226(4):283-7.[Abstract]
